NCT01302808View on ClinicalTrials.gov

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Lung CancerMetastatic Cancer
Interventions
COMBINATION_PRODUCT

Erlotinib plus Romidepsin (8 mg/m^2)

COMBINATION_PRODUCT

Erlotinib plus Romidepsin (10 mg/m^2)

COMBINATION_PRODUCT

Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis

COMBINATION_PRODUCT

(Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis

Trial Locations (1)

75390

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas

Sponsors

Collaborators (2)

Celgene
Genentech, Inc.
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT01302808 - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter